Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431328 | 0.87 | MAPT (0.48) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5510086 | 0.81 | LOXL2 (0.55) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3397178 | 0.81 | LOXL2 (0.58) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4810603 | 0.81 | LOXL2 (0.58) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7152163 | 0.81 | LOXL2 (0.58) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28879947 | 0.81 | LOXL2 (0.58) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9276577 | 0.79 | GABRA1 (0.39) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27670163 | 0.79 | CYP3A4 (0.45) | LOXL2MAPTSMN1; SMN2RAB9ANCF1 | |
| SCHEMBL27594301 | 0.78 | LOXL2 (0.55) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3817375 | 0.78 | LOXL2 (0.64) | LOXL2MAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0091790-B1 | PROCESS FOR PREPARING 2-ALKYLAMINO- AND 2-AMINO-5-ALKYLPYRIDINES | REILLY INDUSTRIES, INC. (US) | 1989-11-15 | — | — | EP | claimed |
| EP-0091790-A2 | Process for preparing 2-alkylamino- and 2-amino-5-alkylpyridines | REILLY INDUSTRIES, INC. (US) | 1983-10-19 | — | — | EP | claimed |
| US-4405790-A | FROM 3-ALKYLPYRIDINE; SODIUM ALKYLAMIDE | REILLY TAR & CHEMICAL CORP. (US) | 1983-09-20 | — | — | US | claimed |
| US-4040970-A | WITH COPOLYMER FOR RENDERING THE TONER NEGATIVELY CHARGEABLE | CANON KABUSHIKI KAISHA (JA) | 1977-08-09 | — | — | US | claimed |
| US-3977983-A | Liquid developer for use in development of an electrostatic latent image comprising a copolymer containing an amino group converted into a quaternary ammonium salt or hydroxide | CANON KABUSHIKI KAISHA (JA) | 1976-08-31 | — | — | US | claimed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-8871756-B2 | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease | HOFFMANN-LA ROCHE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| US-20100247938-A1 | MATERIAL FOR THREE-DIMENSIONAL MODELING, PROCESS FOR PRODUCING THREE-DIMENSIONAL MODEL, AND THREE-DIMENSIONAL MODEL | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-5093333-A | N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0091790-B1 | PROCESS FOR PREPARING 2-ALKYLAMINO- AND 2-AMINO-5-ALKYLPYRIDINES | REILLY INDUSTRIES, INC. (US) | 1989-11-15 | — | — | EP | disclosed |
| EP-0091790-A2 | Process for preparing 2-alkylamino- and 2-amino-5-alkylpyridines | REILLY INDUSTRIES, INC. (US) | 1983-10-19 | — | — | EP | disclosed |
| US-4405790-A | FROM 3-ALKYLPYRIDINE; SODIUM ALKYLAMIDE | REILLY TAR & CHEMICAL CORP. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4110244-A | Photochromic plastic material | AMERICAN OPTICAL CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4049846-A | Photochromic plastic materials | AMERICAN OPTICAL CORPORATION (US) | 1977-09-20 | — | — | US | disclosed |
| US-4040970-A | WITH COPOLYMER FOR RENDERING THE TONER NEGATIVELY CHARGEABLE | CANON KABUSHIKI KAISHA (JA) | 1977-08-09 | — | — | US | disclosed |
| US-3977983-A | Liquid developer for use in development of an electrostatic latent image comprising a copolymer containing an amino group converted into a quaternary ammonium salt or hydroxide | CANON KABUSHIKI KAISHA (JA) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | LOXL2 4242/4885MAPT 4392/4885MEN1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.